COX-2 Safety Review Will Explore Possible Mechanisms To Explain Risk

Briefing materials for advisory committee meeting suggest that FDA believes cardiovascular safety issues with Vioxx represent a class effect. Committee will be asked for views on whether COX-2s should stay on the market – after being reminded of "hope" for GI safety advantage that drove development.